REPL · NASDAQ · STOCK
Replimune Group, Inc.
$13.67
52W $1.50 – $14.14
54/100
$1.15B
-4.0
0.90
Is REPL Bullish or Bearish?
Mixed.
Innellis AI committee rates Replimune Group, Inc. (REPL) Watch with a composite score of 54/100
, based on 5 analysts with 40% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +5.95 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.05 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 96.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.20 across 30 articles, 14d) — News
Bear Case
- ROE of only -128.6% -- cheap may mean cheap for a reason — Value
- RSI at 70 is in overbought territory — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 96.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
54/100
Agreement
40%
Analysts
5
Conviction
Contested
Sector Rank
Top 89%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -128.6% -- cheap may mean cheap for a reason
Technical Analyst
neutral
51
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 70 is in overbought territory
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 96.8% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 30 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
70.3
Overbought
MACD Histogram
0.501
Bullish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Mixed
Bollinger %B
0.84
Inside Bands
Price vs Moving Averages
EMA 9
$11.93
Above
EMA 21
$10.88
Above
EMA 50
$9.77
Above
EMA 200
$8.24
Above
Fundamental Analysis
Valuation
69
Profitability
0
Financial Health
96
Cash Flow
15
Valuation
P/E Ratio
-4.0×
P/B Ratio
7.62×
PEG Ratio
0.67
Dividend Yield
0.00%
52W High
$14.14
52W Low
$1.50
Quality & Growth
ROE
-18893.8%
ROA
-9445.0%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.67
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -4.0 (inexpensive relative to a 15-40x range); Price-to-book of 7.6x; PEG ratio of 0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -188.9%; Return on assets of -94.4%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 4.79 (healthy short-term liquidity); Debt-to-equity of 0.67; Free cash flow per share is negative (-3.07); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full REPL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →